Barclays
NGNE icon

Barclays’s Neurogene NGNE Stock Holding History

Barclays’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$55.5K Sell
2,751
-12,624
-82% -$245K ﹤0.01% 4279
2025
Q4 		$317K Buy
15,375
+448
+3% +$11.2K ﹤0.01% 4103
2025
Q3 		$259K Sell
14,927
-3,084
-17% -$61.9K ﹤0.01% 4178
2025
Q2 		$269K Buy
18,011
+3,782
+27% +$59.3K ﹤0.01% 4102
2025
Q1 		$167K Sell
14,229
-3,304
-19% -$57.4K ﹤0.01% 4146
2024
Q4 		$401K Buy
17,533
+2,674
+18% +$99.5K ﹤0.01% 3959
2024
Q3 		$623K Buy
14,859
+11,316
+319% +$439K ﹤0.01% 3639
2024
Q2 		$129K Sell
3,543
-8,457
-70% -$298K ﹤0.01% 3789
2024
Q1 		$611K Buy
+12,000
New +$401K ﹤0.01% 3466
2023
Q3 		– Sell
-8
Closed -$135 – 4667
2023
Q2 		$135 Sell
8
-257
-97% -$4.21K ﹤0.01% 4432
2023
Q1 		$3.7K Sell
265
-22,348
-99% -$262K ﹤0.01% 4853
2022
Q4 		$230K Hold
22,613
– – ﹤0.01% 3765
2022
Q3 		$289K Hold
22,613
– – ﹤0.01% 2996
2022
Q2 		$466K Sell
22,613
-285
-1% -$6.95K ﹤0.01% 2915
2022
Q1 		$861K Buy
+22,898
New +$1.34M ﹤0.01% 2525
2019
Q1 		– Sell
-480
Closed -$21K – 7221
2018
Q4 		$21K Sell
480
-400
-45% -$19.5K ﹤0.01% 5876
2018
Q3 		$52K Buy
+880
New +$51.9K ﹤0.01% 6058
2018
Q2 		– Sell
-3
Closed -$782 – 7172
2018
Q1 		$1K Hold
3
– – ﹤0.01% 6963
2017
Q4 		$1K Buy
+3
New +$703 ﹤0.01% 6848
2017
Q3 		– Sell
-10
Closed -$3K – 6972
2017
Q2 		$3K Buy
10
+1
+11% +$286 ﹤0.01% 6351
2017
Q1 		$3K Sell
9
-42
-82% -$14.8K ﹤0.01% 6391
2016
Q4 		$16K Buy
51
+18
+55% +$4.84K ﹤0.01% 5727
2016
Q3 		$9K Buy
33
+22
+200% +$4.43K ﹤0.01% 5832
2016
Q2 		$1K Buy
11
+5
+83% +$795 ﹤0.01% 6132
2016
Q1 		$1K Sell
6
-8
-57% -$1.55K ﹤0.01% 5983
2015
Q4 		$3K Buy
+14
New +$3.68K ﹤0.01% 5682

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Barclays's NGNE Position: Q1 2026 in Review

Barclays reduced its Neurogene (NGNE) stake by 82% in Q1 2026, selling an estimated $245K and leaving 2,751 shares worth $55.5K. The position accounts for ﹤0.01% of the portfolio, ranked #4279.

Barclays first reported a position in NGNE in Q4 2015 and has held it in 26 quarters since. The position peaked at $861K in Q1 2022. 96 funds tracked by Wall St. Rank hold NGNE as of Q1 2026.

  • Barclays held 2,751 shares of Neurogene worth $55.5K as of Q1 2026.
  • Barclays sold 12,624 Neurogene shares in Q1 2026, an estimated $245K.
  • Neurogene made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4279 holding.
  • Barclays first reported a position in Neurogene in Q4 2015 and has held it in 26 quarters since.
  • Barclays's Neurogene position peaked at $861K in Q1 2022.
  • 96 funds tracked by Wall St. Rank held Neurogene as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.